Micro Interventional Devices

Executive Summary

Micro Interventional Devices (MID) is a privately held medical device company pioneering catheter-based technologies for transcatheter cardiac repair (TCR), with an initial focus on mitral and tricuspid valve repair. Unlike traditional open-heart surgery requiring cardiopulmonary bypass, MID's percutaneous approach aims to replicate established surgical procedures through minimally invasive access. Founded in 2010 and headquartered in New Hope, Pennsylvania, the company leverages proprietary device designs to address significant unmet needs in structural heart disease. While MID has not yet disclosed specific funding rounds or clinical stage, its technology targets a large and growing market segment, driven by aging populations and the shift toward less invasive interventions. The company's success hinges on demonstrating safety and efficacy in human trials, navigating regulatory pathways, and securing strategic partnerships or financing to support commercialization.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation for mitral valve repair system60% success
• Q4 2026Series B funding round or strategic partnership announcement50% success
• Q1 2027FDA investigational device exemption (IDE) submission for tricuspid valve program40% success